President Trump’s proposed research rule is stirring controversy. Many are raising concerns over this administration’s plan, claiming it could politicize science funding and jeopardize the U.S.’s leadership in biomedical research. Opposition is coming from patient groups, scientists, bipartisan lawmakers, and pharmaceutical companies.
The White House Office of Management and Budget introduced the rule, attracting nearly 342,000 public comments. Critics argue that the rule would solidify policies attempted through executive orders, requiring senior officials to review all federal awards. These officials could deny funding if projects don’t align with the president’s agenda. Existing awards could also be canceled without clear reasons and with limited recourse.
A significant point of contention is the rule’s impact on research related to diversity, equity, and inclusion. It would also largely prohibit international collaborations, posing a challenge as China advances in global scientific leadership.
The administration defends the rule, stating that it aims to enhance transparency and curb government waste and fraud. However, 57 patient advocacy organizations, representing millions of Americans with various diseases, have urged Congress to act. They warn that the rule might harm America’s standing as a global leader in science, especially against China. Patients in clinical trials could lose access to advanced treatments, leading to wasted federal investment and lost hope.
Nathaniel Weixel and Joseph from The Hill provide insights into Washington’s influence on healthcare. The Department of Health and Human Services (HHS) reported $5.56 billion in expected recoveries and projected savings over six months, with over 1,200 individuals and companies banned from federal programs.
Meanwhile, the sudden death of Sen. Lindsey Graham (R-SC) at 71 due to an aortic dissection highlights this rare yet often fatal condition. D.C.’s chief medical examiner attributed the death to arteriosclerosis cardiovascular disease.
The World Health Organization (WHO) reports a second U.S. citizen diagnosed with Ebola, who was transferred to Germany for treatment. This individual, a humanitarian worker, was admitted to Frankfurt University Hospital.
Upcoming events include the Senate HELP Committee’s confirmation hearing for nominees for CDC director and the HHS Assistant Secretary for Preparedness and Response.
States are also suing over mental health grants. Attorneys general claim the Department of Education unlawfully planned to cut grants for school mental health. This lawsuit aims to uphold a prior injunction against the grant termination.
In local news, as the GOP raises fraud claims, California Governor Newsom supports Medicaid spending on housing and food. In Southwest Virginia, eight school-based health clinics are closing due to federal funding issues. Missouri’s governor has signed a bipartisan healthcare bill into law.
From other outlets, Trump’s HHS has dropped threats to withhold Medicare and Medicaid funds over trans care, Bayer seeks to end litigation after a Supreme Court win, and families face financial difficulties due to Medicaid funding cuts.